Stepwise Strategy for Treatment of Atrial Fibrillation Substrate Extended Study

Enrolling by invitation

Conditions studied: Atrial Fibrillation

In brief

This is an observational, bidirectional cohort study, aiming to establish a long-term registry of adult patients with Persistent atrial fibrillation (ps-AF) in Southwest China to characterize patient profiles and evaluate embolism risk, rate control, rhythm control and complication management and outcomes over 5 years' follow-up. The objectives of the study are to: Describe the demographic, clinical, and treatment characteristics of ps-AF patients across Southwest China and assess the effectiveness and safety of various AF treatment strategies, including oral anticoagulation, electrical cardioversion, catheter ablation, and left atrial appendage closure, in routine clinical practice. Identify patient- and treatment-related factors that influence therapeutic outcomes. Explore the characteristics of imaging multi-omics and blood multi-omics during follow-up. Explore the role of advanced technologies and artificial intelligence in improving procedural performance, risk stratification, and clinical decision-making in AF care. Participants will undergo standardized baseline evaluation and longitudinal follow-up to collect data on heart rhythm monitoring, treatment exposures, healthcare utilization, clinical events, and patient-reported outcomes. This cohort will generate real-world evidence to inform personalized and evidence-based management of AF.

Key facts

Study ID

NCT07380620

Run by

Yuehui Yin

People needed

5000

Starts

2025-10-09

Expected to finish

2035-12-31

Last updated by the study team

2026-02-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged ≥18 years;
• diagnosed with persistent atrial fibrillation (ps-AF), defined as episodes lasting >7 days or requiring pharmacological/electrical cardioversion for rhythm restoration;
• Residing in Southwest China and capable of cooperating with long-term follow-up management;
• History of ps-AF treatment with complete medical records, and voluntary signing of the informed consent for long-term follow-up.

You may not qualify if…

• Comorbid severe hepatic/renal dysfunction or malignant tumors;
• Estimated survival period <1 year.

Where it is running

• the second affiliated hospital of CQMU — Chongqing, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.